Eisai Co. Ltd. (ESAIY PINK) stock market data APIs
$7.4522
0(0%)
as of May 8, 2026
Try our APIs with
free plan!
Eisai Co. Ltd. Financial Data Overview
Price chart is built with
Anychart
Eisai Co., Ltd. engages in the research and development, manufacture, sale, and import and export of pharmaceuticals in India. It also offers prescription medicines. In addition, the company focuses on neurology and oncology and therapeutic areas. The company was formerly known as Nihon Eisai Co., Ltd. and changed its name to Eisai Co., Ltd. in 1955. Eisai Co., Ltd. was incorporated in 1941 and is headquartered in Tokyo, Japan.
Prev. Close
7.4522
Open
7.4935
High
7.5132
Low
7.352
52 wk Range
5.7025-8.5077
Market Cap
8 378 M
P/E Ratio
26.5357
Shares Outstanding
1 128 M
Revenue
808 186 M
Dividends (Yield)
0.036
Beta
-0.114
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Eisai Co. Ltd. data using free add-ons & libraries
Get Eisai Co. Ltd. Fundamental Data
Eisai Co. Ltd. Fundamental data includes:
- Net Revenue: 808 186 M
- EBITDA: 89 009 M
- Earnings Per Share: 0
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2026-05-12
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Eisai Co. Ltd. News
New
Eisai (TSE:4523) Valuation Check After Recent Share Price Pullback And LEQEMBI Growth Story
Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge. Eisai stock performance snapshot Eisai (TSE:4523) has recently drawn attention after a one...
Leqembi® Iqlik™ PDUFA date updated to August 24 in the U.S.
STOCKHOLM, May 8, 2026 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today announced that the U.S. Food and Drug Administration (FDA) has extended the review period by...
Update on FDA Priority Review of LEQEMBI® IQLIK™ (lecanemab-irmb) Subcutaneous Injection as a Starting Dose for Early Alzheimer's Disease
TOKYO and CAMBRIDGE, Mass., May 8, 2026 /PRNewswire/ -- Eisai Co., Ltd. and Biogen Inc. (Nasdaq: BIIB) today announced that the U.S. Food and Drug Administration (FDA) has extended the review period b...
Update on FDA Priority Review of LEQEMBI® IQLIK™ (lecanemab-irmb) Subcutaneous Injection as a Starting Dose for Early Alzheimer’s Disease
Biogen Inc. TOKYO and CAMBRIDGE, Mass., May 08, 2026 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. and Biogen Inc. (Nasdaq: BIIB) today announced that the U.S. Food and Drug Administration (FDA) has extended t...
Get Eisai Co. Ltd. fresh news feed via Financial News API
Corporate Events Calendar & News package for
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
